Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 3Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Renal Insufficiency 1Neoplasms 1Liver Diseases 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × rubitecan × Clear all
NCT00113113 2024-08-02

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Astex Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled

Liver Diseases, Neoplasms, Renal Insufficiency

NCT00006047 2012-09-26

Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
44 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡